Register Interest

Zucero Therapeutics

  • Zucero is an Australian-based, publicly unlisted biotechnology company focused on the development of pixatimod, an immunotherapy for the treatment of cancer.

  • Pixatimod successfully completed safety evaluation in a Phase 1a clinical trial. It is currently under investigation in a Phase 1b study in combination with Opdivo® (immune checkpoint inhibitor) for pancreatic cancer, and new investigations in colon cancer are now being planned.